Medical/Pharmaceuticals
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...
2023-05-29 09:42
2250
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...
2023-05-28 21:00
3025
Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system
SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...
2023-05-26 22:08
3974
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
* ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer withESR1-mutations (ESR1-mut) that are found in up to 40% of tumors * In patients whose tumors har...
2023-05-26 20:37
2931
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...
2023-05-26 20:00
2347
FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health
Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...
2023-05-26 13:42
2263
Guizhou uses big data tech to develop smart healthcare
GUIYANG, China, May 26, 2023 /PRNewswire/ -- A news report from Huanqiu.com: "It always took me over half a day to take my child to go to the county and see a doctor for a minor illness several years ago. Now we can get remote diagnosis and treatment services from the higher-level hospital when w...
2023-05-26 11:00
3171
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference
SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...
2023-05-26 10:01
3197
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors * The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical canc...
2023-05-26 09:41
3100
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
* Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis * Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) * Bentrio efficacy and tolerability rated as "good" or "ve...
2023-05-26 08:00
3902
Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting
SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting,June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal's two leading assets...
2023-05-26 06:00
2234
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...
2023-05-26 06:00
2371
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation ofpatients' immune system against cancer cells. - In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73High and PD-L1 T...
2023-05-26 05:01
2316
Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting
- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader of AI-powered cancer diagnostics and therapeutics soluti...
2023-05-26 05:00
2241
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan
SAN DIEGO, May 26, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce that their LeukoStrat CDxFLT3 Mutation Assay® has received updated reimbursement byJapan's Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosedFLT3-ITD positive acute my...
2023-05-26 05:00
2160
Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023
SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical developm...
2023-05-25 22:00
2042
Leading New Zealand cancer research 'super-charged' by data privacy startup
DUNEDIN, New Zealand, May 25, 2023 /PRNewswire/ -- Two top medical research and biotech innovators today announce a partnership that will supercharge cancer research while providing new levels of health data privacy. Amaroq Therapeutics, a world-leading company based in New Zealand focused on de...
2023-05-25 21:00
2032
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders * Phase 1 clinical trial is ex...
2023-05-25 19:00
2391
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey MELBOURNE, Australia and INDIANAPOLIS, May 2...
2023-05-25 19:00
2024
Partnership between Thermo Fisher Scientific and BRIN to Strengthen Research Infrastructure and Capabilities in Indonesia
Collaboration to enhance BRIN's scientific and innovation infrastructure and talent SINGAPORE, May 25, 2023 /PRNewswire/ -- Thermo Fisher, the world leader in serving science, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency ofIndonesia (BRIN, Bad...
2023-05-25 18:04
2904
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:076th HIIFF Closes with Golden Coconut Award Ceremony
[Picked up by 282 media titles]
2024-12-11 22:19
Most Read
Macaronesian Stories, a moving campaign to rebuild a dream buried by La Palma's volcano in the Canary Islands
2024-12-13 22:46
3710
Agoda releases generative AI film to capture the joy of travel
2024-12-10 10:00
3702
Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
2024-12-08 00:23
3561
